ReviewCurrent pharmaceutical design2013
Rejuvenating sirtuins: the rise of a new family of cancer drug targets.
Review in Current pharmaceutical design, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease.Heliyon · 2024Review
- Interplay Between the Circadian Clock and Sirtuins.International journal of molecular sciences · 2024Review
- Review
- The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance.Frontiers in oncology · 2022Review
- Differential modulation of SIRT6 deacetylase and deacylase activities by lysine-based small molecules.Molecular diversity · 2020Article
- Structural Insight into the Interactions between Structurally Similar Inhibitors and SIRT6.International journal of molecular sciences · 2020Article
- The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- Downregulated SIRT6 and upregulated NMNAT2 are associated with the presence, depth and stage of colorectal cancer.Oncology letters · 2018Article
- Nicotinic acid: A case for a vitamin that moonlights for cancer?Cell cycle (Georgetown, Tex.) · 2017Article
- Chromatin determinants impart camptothecin sensitivity.EMBO reports · 2017Article
- Article
- Sirtuins, Cell Senescence, and Vascular Aging.The Canadian journal of cardiology · 2016Review
- Exploring NAD+ metabolism in host-pathogen interactions.Cellular and molecular life sciences : CMLS · 2016Review
- Article
- A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells.Anticancer research · 2016Article
- Epigenetics in Brain Tumors: HDACs Take Center Stage.Current neuropharmacology · 2016Review
- High expression of Sirt7 served as a predictor of adverse outcome in breast cancer.International journal of clinical and experimental pathology · 2015Article
- SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1.International journal of clinical and experimental medicine · 2015Article
- Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes.Computational and structural biotechnology journal · 2015Review
- Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.